Article Sidebar
Published:
May 31, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Sparteine exerts anticancer effect on human cervical cancer cells via induction of apoptosis, G0/G1 cell cycle arrest and inhibition of VEGFR2 signalling pathway
Abstract
Purpose: To investigate the anticancer effects of sparteine against human cervical cancer.
Methods: Cell viability was determined by CCK8 assay, while 4′, 6-diamidino-2-phenylindole (DAPI) staining was used for determination of apoptosis. Cell cycle analysis was done with flow cytometry, while cell invasion was monitored using Transwell invasion assays. Protein expressions were determined using Western blotting.
Results: The results revealed that sparteine inhibited the viability of cervical cancer cells with halfmaximal inhibitory concentration (IC50) ranging from 10 to 25 µM. Sparteine exerted more profound antiproliferative effects on DoTc2 cells, with IC50 of 10 µM. However, minimal cytotoxicity was observed in normal cervical cells, as evident from the IC50 of 80 µM. Sparteine triggered the generation of ROS and apoptotic cell death in DoTc2 cells. The induction of apoptosis was accompanied by upregulation of Bax expression and downregulation of Bcl-2 expression. Sparteine caused arrest of DoTc2 cells at the G0/G1 phase of the cell cycle, and suppressed the expressions of cyclin A and cyclin B1. Transwell assay data showed that sparteine decreased the invasion ability of DoTc2 cells. Sparteine also inhibited the phosphorylation of VGFR2 in a concentration-dependent manner.
Conclusion: Sparteine exhibits significant anticancer activity and may prove beneficial in cervical cancer chemotherapy.
